Advancing  ||| S:0 E:10 ||| VBG
neurosurgery  ||| S:10 E:23 ||| NN
through  ||| S:23 E:31 ||| IN
translational  ||| S:31 E:45 ||| JJ
research  ||| S:45 E:54 ||| NN
Every  ||| S:54 E:60 ||| DT
year ||| S:60 E:64 ||| NN
,  ||| S:64 E:66 ||| ,
the  ||| S:66 E:70 ||| DT
number  ||| S:70 E:77 ||| NN
of  ||| S:77 E:80 ||| IN
published  ||| S:80 E:90 ||| JJ
research  ||| S:90 E:99 ||| NN
articles  ||| S:99 E:108 ||| NNS
increases  ||| S:108 E:118 ||| VBZ
significantly ||| S:118 E:131 ||| RB
.  ||| S:131 E:133 ||| .
However ||| S:133 E:140 ||| RB
,  ||| S:140 E:142 ||| ,
many  ||| S:142 E:147 ||| JJ
potentially  ||| S:147 E:159 ||| RB
useful  ||| S:159 E:166 ||| JJ
ideas  ||| S:166 E:172 ||| NNS
are  ||| S:172 E:176 ||| VBP
lost  ||| S:176 E:181 ||| VBN
in  ||| S:181 E:184 ||| IN
this  ||| S:184 E:189 ||| DT
flood  ||| S:189 E:195 ||| NN
of  ||| S:195 E:198 ||| IN
data ||| S:198 E:202 ||| NNS
.  ||| S:202 E:204 ||| .
Translational  ||| S:204 E:218 ||| JJ
research  ||| S:218 E:227 ||| NN
provides  ||| S:227 E:236 ||| VBZ
a  ||| S:236 E:238 ||| DT
framework  ||| S:238 E:248 ||| NN
through  ||| S:248 E:256 ||| IN
which  ||| S:256 E:262 ||| WDT
investigators  ||| S:262 E:276 ||| NNS
or  ||| S:276 E:279 ||| CC
laboratories  ||| S:279 E:292 ||| NNS
can  ||| S:292 E:296 ||| MD
maximize  ||| S:296 E:305 ||| VB
the  ||| S:305 E:309 ||| DT
likelihood  ||| S:309 E:320 ||| NN
that  ||| S:320 E:325 ||| IN
the  ||| S:325 E:329 ||| DT
product  ||| S:329 E:337 ||| NN
of  ||| S:337 E:340 ||| IN
their  ||| S:340 E:346 ||| PRP$
research  ||| S:346 E:355 ||| NN
will  ||| S:355 E:360 ||| MD
be  ||| S:360 E:363 ||| VB
adopted  ||| S:363 E:371 ||| VBN
in  ||| S:371 E:374 ||| IN
medical  ||| S:374 E:382 ||| JJ
practice ||| S:382 E:390 ||| NN
.  ||| S:390 E:392 ||| .
There  ||| S:392 E:398 ||| EX
are  ||| S:398 E:402 ||| VBP
2  ||| S:402 E:404 ||| CD
recognizable  ||| S:404 E:417 ||| JJ
models  ||| S:417 E:424 ||| NNS
of  ||| S:424 E:427 ||| IN
translation  ||| S:427 E:439 ||| JJ
appropriate  ||| S:439 E:451 ||| JJ
for  ||| S:451 E:455 ||| IN
the  ||| S:455 E:459 ||| DT
majority  ||| S:459 E:468 ||| NN
of  ||| S:468 E:471 ||| IN
research ||| S:471 E:479 ||| NN
:  ||| S:479 E:481 ||| :
investigator  ||| S:481 E:494 ||| NN
driven  ||| S:494 E:501 ||| VBN
and  ||| S:501 E:505 ||| CC
industry  ||| S:505 E:514 ||| NN
enabled ||| S:514 E:521 ||| VBD
.  ||| S:521 E:523 ||| .
Investigator-driven  ||| S:523 E:543 ||| JJ
research  ||| S:543 E:552 ||| NN
has  ||| S:552 E:556 ||| VBZ
more  ||| S:556 E:561 ||| JJR
range  ||| S:561 E:567 ||| NN
because  ||| S:567 E:575 ||| IN
it  ||| S:575 E:578 ||| PRP
does  ||| S:578 E:583 ||| VBZ
not  ||| S:583 E:587 ||| RB
have  ||| S:587 E:592 ||| VBP
to  ||| S:592 E:595 ||| TO
consider  ||| S:595 E:604 ||| VB
the  ||| S:604 E:608 ||| DT
profit  ||| S:608 E:615 ||| NN
margin  ||| S:615 E:622 ||| NN
of  ||| S:622 E:625 ||| IN
research ||| S:625 E:633 ||| NN
,  ||| S:633 E:635 ||| ,
but  ||| S:635 E:639 ||| CC
it  ||| S:639 E:642 ||| PRP
is  ||| S:642 E:645 ||| VBZ
a  ||| S:645 E:647 ||| DT
slow  ||| S:647 E:652 ||| JJ
process ||| S:652 E:659 ||| NN
.  ||| S:659 E:661 ||| .
The  ||| S:661 E:665 ||| DT
industry-enabled  ||| S:665 E:682 ||| JJ
model  ||| S:682 E:688 ||| NN
accelerates  ||| S:688 E:700 ||| VBZ
the  ||| S:700 E:704 ||| DT
translational  ||| S:704 E:718 ||| JJ
research  ||| S:718 E:727 ||| NN
process  ||| S:727 E:735 ||| NN
through  ||| S:735 E:743 ||| IN
the  ||| S:743 E:747 ||| DT
power  ||| S:747 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
industry  ||| S:756 E:765 ||| NN
funding  ||| S:765 E:773 ||| NN
but  ||| S:773 E:777 ||| CC
is  ||| S:777 E:780 ||| VBZ
interested  ||| S:780 E:791 ||| VBN
primarily  ||| S:791 E:801 ||| RB
in  ||| S:801 E:804 ||| IN
products  ||| S:804 E:813 ||| NNS
with  ||| S:813 E:818 ||| IN
potential  ||| S:818 E:828 ||| JJ
for  ||| S:828 E:832 ||| IN
profit ||| S:832 E:838 ||| NN
.  ||| S:838 E:840 ||| .
Two  ||| S:840 E:844 ||| CD
cases  ||| S:844 E:850 ||| NNS
are  ||| S:850 E:854 ||| VBP
examined  ||| S:854 E:863 ||| VBN
to  ||| S:863 E:866 ||| TO
illustrate  ||| S:866 E:877 ||| VB
different  ||| S:877 E:887 ||| JJ
methods  ||| S:887 E:895 ||| NNS
of  ||| S:895 E:898 ||| IN
partnering  ||| S:898 E:909 ||| NN
with  ||| S:909 E:914 ||| IN
industry ||| S:914 E:922 ||| NN
.  ||| S:922 E:924 ||| .
IMRIS  ||| S:924 E:930 ||| NNP
is  ||| S:930 E:933 ||| VBZ
a  ||| S:933 E:935 ||| DT
company  ||| S:935 E:943 ||| NN
founded  ||| S:943 E:951 ||| VBN
by  ||| S:951 E:954 ||| IN
investigators  ||| S:954 E:968 ||| NNS
to  ||| S:968 E:971 ||| TO
distribute  ||| S:971 E:982 ||| VB
intraoperative  ||| S:982 E:997 ||| JJ
magnetic  ||| S:997 E:1006 ||| JJ
resonance  ||| S:1006 E:1016 ||| NN
imaging  ||| S:1016 E:1024 ||| NN
technology  ||| S:1024 E:1035 ||| NN
based  ||| S:1035 E:1041 ||| VBN
on  ||| S:1041 E:1044 ||| IN
a  ||| S:1044 E:1046 ||| DT
movable  ||| S:1046 E:1054 ||| JJ
high-field  ||| S:1054 E:1065 ||| JJ
magnet ||| S:1065 E:1071 ||| NN
.  ||| S:1071 E:1073 ||| .
It  ||| S:1073 E:1076 ||| PRP
took  ||| S:1076 E:1081 ||| VBD
7  ||| S:1081 E:1083 ||| CD
years  ||| S:1083 E:1089 ||| NNS
for  ||| S:1089 E:1093 ||| IN
IMRIS  ||| S:1093 E:1099 ||| NNP
to  ||| S:1099 E:1102 ||| TO
make  ||| S:1102 E:1107 ||| VB
its  ||| S:1107 E:1111 ||| PRP$
first  ||| S:1111 E:1117 ||| JJ
sale ||| S:1117 E:1121 ||| NN
,  ||| S:1121 E:1123 ||| ,
but  ||| S:1123 E:1127 ||| CC
it  ||| S:1127 E:1130 ||| PRP
is  ||| S:1130 E:1133 ||| VBZ
now  ||| S:1133 E:1137 ||| RB
a  ||| S:1137 E:1139 ||| DT
successful  ||| S:1139 E:1150 ||| JJ
company ||| S:1150 E:1157 ||| NN
.  ||| S:1157 E:1159 ||| .
With  ||| S:1159 E:1164 ||| IN
neuroArm ||| S:1164 E:1172 ||| NNP
,  ||| S:1172 E:1174 ||| ,
a  ||| S:1174 E:1176 ||| DT
surgical  ||| S:1176 E:1185 ||| JJ
robot ||| S:1185 E:1190 ||| NN
,  ||| S:1190 E:1192 ||| ,
investigators  ||| S:1192 E:1206 ||| NNS
decided  ||| S:1206 E:1214 ||| VBD
to  ||| S:1214 E:1217 ||| TO
sell  ||| S:1217 E:1222 ||| VB
the  ||| S:1222 E:1226 ||| DT
intellectual  ||| S:1226 E:1239 ||| JJ
property  ||| S:1239 E:1248 ||| NN
to  ||| S:1248 E:1251 ||| TO
an  ||| S:1251 E:1254 ||| DT
established  ||| S:1254 E:1266 ||| JJ
company  ||| S:1266 E:1274 ||| NN
to  ||| S:1274 E:1277 ||| TO
ensure  ||| S:1277 E:1284 ||| VB
successful  ||| S:1284 E:1295 ||| JJ
global  ||| S:1295 E:1302 ||| JJ
commercialization ||| S:1302 E:1319 ||| NN
.  ||| S:1319 E:1321 ||| .
Translational  ||| S:1321 E:1335 ||| JJ
research  ||| S:1335 E:1344 ||| NN
advances  ||| S:1344 E:1353 ||| NNS
medicine  ||| S:1353 E:1362 ||| NN
by  ||| S:1362 E:1365 ||| IN
creating  ||| S:1365 E:1374 ||| VBG
and  ||| S:1374 E:1378 ||| CC
distributing  ||| S:1378 E:1391 ||| VBG
effective  ||| S:1391 E:1401 ||| JJ
solutions  ||| S:1401 E:1411 ||| NNS
to  ||| S:1411 E:1414 ||| TO
contemporary  ||| S:1414 E:1427 ||| JJ
problems ||| S:1427 E:1435 ||| NNS
.  ||| S:1435 E:1437 ||| .
